Home/Biosimilar Atlas/Companies/Coherus BioSciences

Coherus BioSciences

Biosimilar developer, United States. 2 development products across 2 molecules: adalimumab, pegfilgrastim.

First approval in the Atlas: Nov 2018, Udenyca, pegfilgrastim (FDA)

FDAproducts approved2

EMAproducts approved0

MHRAproducts approved0

PMDAproducts approved0

HCproducts approved0

CDSCOproducts approved0

EDEproducts registered0

Connections

2molecules 2products 1 of 7markets 1candidates in trials 4companies on the same molecules

Portfolio by market

Molecule	Product	FDA	EMA	MHRA	PMDA	HC	CDSCO	EDE	Markets
Adalimumab	Yusimry CHS-1420	Dec 2021	·	·	·	·	·	·	1/7
Pegfilgrastim	Udenyca CHS-1701	Nov 2018	withdrawn	·	·	·	·	·	1/7

Month shown is the first approval or registration of that product in that market.

In development

ClinicalTrials.gov lists one comparative trial sponsored by Coherus BioSciences for one molecule: etanercept. Candidates without an approval yet in the seven markets: CHS-0214.

Molecule	Candidate	Developer or sponsor	Reference product	Phase	Design	Registry status	Started	Primary completion	In the Atlas	Registry record
Etanercept	CHS-0214	Coherus BioSciences	Enbrel	Phase 3	Comparative efficacy	Completed	May 2014	Oct 2015	no approval in the seven markets	NCT02115750

Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.

Companies on the same molecules

Developers whose portfolios overlap most with Coherus BioSciences, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Fresenius KabiTwo shared molecules: adalimumab, pegfilgrastim5 molecules in its portfolio Mochida PharmaceuticalTwo shared molecules: adalimumab, pegfilgrastim5 molecules in its portfolio PfizerTwo shared molecules: adalimumab, pegfilgrastim7 molecules in its portfolio SandozTwo shared molecules: adalimumab, pegfilgrastim10 molecules in its portfolio

Chronology

FDANov 2018Udenyca, pegfilgrastim
FDADec 2021Yusimry, adalimumab

Compare Coherus BioSciences with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Data current to September 2026.